@article{merle:hal-04265920,
TITLE = {Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial},
AUTHOR = {Merle, Philippe and Kudo, Masatoshi and Edeline, Julien and Bouattour, Mohamed and Cheng, Ann-Lii and Chan, Stephen and Yau, Thomas and Garrido, Marcelo and Knox, Jennifer and Daniele, Bruno and Breder, Valeriy and Lim, Ho Yeong and Ogasawara, Sadahisa and Cattan, St{\'e}phane and Chao, Yee and B. Siegel, Abby and Martinez-Forero, Iv{\'a}n and Wei, Ziwen and Liu, C and Finn, Richard},
URL = {https://hal.science/hal-04265920},
JOURNAL = {Liver Cancer},
PUBLISHER = {S. Karger},
VOLUME = {12},
NUMBER = {4},
PAGES = {309-320},
YEAR = {2023},
MONTH = Jan, DOI = {10.1159/000529636},
KEYWORDS = {Pembrolizumab ; Medicine ; Placebo ; Sorafenib ; Internal medicine ; Clinical endpoint ; Randomization ; Gastroenterology ; Hepatocellular carcinoma ; Randomized controlled trial ; Oncology ; Cancer ; Immunotherapy ; Pathology ; Alternative medicine},
PDF = {https://hal.science/hal-04265920/file/000529636.pdf},
HAL_ID = {hal-04265920},
HAL_VERSION = {v1},
}